Immunocore
Immunocore is a commercial-stage biotechnology company pioneering T cell receptor (TCR) bispecific immunotherapies. The company discovered, developed, and commercialized the world's first approved TCR therapy, KIMMTRAK (tebentafusp), for HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma. Its proprietary ImmTAX platform is designed to activate the immune system to make infected or tumor cells visible and destroy them, or turn off immune responses in autoimmune diseases. The company has a diverse pipeline targeting cancer, infectious diseases, and autoimmune conditions.
Public Company
Immunocore is publicly traded
IPO'd on February 5, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under IMCR.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2008
Employees
201–500
Total Funding
$565M
4 rounds
Funding
Total raised $565M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series C (Crossover)
Date
January 2021
Amount
$75M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| January 2021 | Series C (Crossover) | $75M | — | Not disclosed |
| March 2, 2020 | Series B | $130M | — | General Atlantic |
| September 18, 2017 | Strategic investment (Gates Foundation PRI) | $40M | — | Bill & Melinda Gates Foundation |
Leadership
Bahija Jallal
Chief Executive Officer
John Bell
Chairman
Travis Coy
Executive Vice President, Chief Financial Officer, Head of Corporate Development
David Berman
Head of Research and Development
Mohammed Dar
Head of Clinical Development, Chief Medical Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Immatics
German biotech developing TCR-T therapies and TCR bispecifics with protein drug pipeline at preclinical stage.
Adaptimmune Therapeutics
Develops TCR-based cell therapies with proprietary SPEAR T-cells targeting solid tumors.
Fate Therapeutics
Develops engineered T cell therapies for oncology and other diseases.
Atara Biotherapeutics
Clinical-stage biopharmaceutical company developing T-cell immunotherapies.
Immunocore Investment FAQ
Immunocore FAQ
Yes, Immunocore is publicly traded under the ticker symbol IMCR on the NASDAQ. The company went public in February 5, 2021.
Immunocore trades under the ticker symbol IMCR on the NASDAQ. It began trading in February 5, 2021.
Immunocore (IMCR on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker IMCR to place an order.
Immunocore went public in February 5, 2021 via ipo. Immunocore completed its IPO on NASDAQ on February 5, 2021, pricing 9.935 million ADSs at $26.00 per share for gross proceeds of approximately $258.3 million.
Immunocore raised $565M across 4 disclosed funding rounds prior to its public listing.
Immunocore is headquartered in Abingdon, Oxon, United Kingdom.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.